Shopping Cart
- Remove All
- Your shopping cart is currently empty
Epcoritamab (GEN3013) is a novel subcutaneous CD3xCD20 bispecific T-cell binding antibody that activates T-cells and directs them to kill malignant CD20(+) B-cells for the study of relapsed or refractory large B-cell lymphoma.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
1 mg | $538 | In Stock | |
5 mg | $1,380 | In Stock | |
10 mg | $2,250 | In Stock | |
25 mg | $3,350 | In Stock | |
50 mg | $4,520 | In Stock |
Description | Epcoritamab (GEN3013) is a novel subcutaneous CD3xCD20 bispecific T-cell binding antibody that activates T-cells and directs them to kill malignant CD20(+) B-cells for the study of relapsed or refractory large B-cell lymphoma. |
In vitro | Epcoritamab (30 ng/mL) was effective in inducing cytotoxicity in the presence of peripheral blood mononuclear cells (PBMC) from healthy donors. [1] |
Cas No. | 2134641-34-0 |
Storage | store at low temperature | store at -20°C | Shipping with blue ice. |
Copyright © 2015-2024 TargetMol Chemicals Inc. All Rights Reserved.